An Amylyx Pharmaceuticals drug developed to slow the progression of amyotrophic lateral sclerosis is now approved, making it just the third FDA-approved treatment for the disease. Amylyx will market its new product under the name “Relyvrio.”
The US Food and Drug Administration will reconvene a meeting of its outside experts to review Amylyx Pharmaceuticals application for its amyotrophic lateral sclerosis treatment, the company said Tuesday.